Organovo Holdings, Inc. is a San Diego-based company specializing in the development of pioneering 3D human tissues for drug discovery. With a strong leadership team and board of directors, the company focuses on creating innovative tissue models that improve epithelial barrier function and reduce fibrosis in conditions such as Crohn's disease and colitis.
Through their pipeline of research and development, Organovo aims to provide groundbreaking solutions for various medical conditions, including non-alcoholic steatohepatitis (NASH). Their commitment to scientific excellence is evident in their publications, press releases, and media coverage, attracting the attention of investors and industry professionals alike.
Generated from the website